Mesenchymal stem cells modified to express lentivirus TNF-α Tumstatin 45-132 inhibit the growth of prostate cancer

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 2, 2011, Pages 433-444

  Zhang, Xu ^a   Xu, Wenrong ^a   Qian, Hui ^a   Zhu, Wei ^a   Zhang, Ruiwen ^b  

^a JIANGSU UNIVERSITY   (China)

^b University of Alabama at Birmingham   (United States)

Author keywords

Gene therapy; Mesenchymal stem cells; Prostate cancer; TNF ; Tumstatin

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TUMSTATIN45 132 TNF; TUMSTATIN45-132-TNF;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL PROLIFERATION; COCULTURE; DRUG SCREENING; ENZYMOLOGY; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; HUMAN; LENTIVIRINAE; MALE; MESENCHYMAL STEM CELL; METABOLISM; MOUSE; NUDE MOUSE; PROSTATE TUMOR; RAT; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE THERAPY; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LENTIVIRUS; MALE; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

LENTIVIRUS;

EID: 79951896266     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00920.x     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, et al Cancer statistics. CA Cancer J Clin. 2007; 57: 43-66.
2. Naitoh J, Belldegrun A. Gene therapy for prostate cancer. Prostate Cancer Prostatic Dis. 1998; 1: 189-96.
3. Shariat SF, Slawin KM. Gene therapy for prostate cancer. Rev Urol. 2000; 2: 81-7.
4. Djavan B, Nasu Y. Prostate cancer gene therapy-what have we learned and where are we going? Rev Urol. 2001; 3: 179-86.
5. Webster WS, Small EJ, Rini BI, Kwon ED. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol. 2005; 23: 8262-9.
6. Pereboeva L, Komarova S, Mikheeva G, et al Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells. 2003; 21: 389-404.
7. Reiser J, Zhang XY, Hemenway CS, et al Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opin Biol Ther. 2005; 5: 1571-84.
8. Hall B, Dembinski J, Sasser AK, et al Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol. 2007; 86: 8-16.
9. Lee K, Majumdar MK, Buyaner D, et al Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol Ther. 2001; 3: 857-66.
10. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008; 15: 739-52.
11. Conget PA, Minguell JJ. Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp Hematol. 2000; 28: 382-90.
12. Komarova S, Kawakami Y, Stoff-Khalili MA, et al Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther. 2006; 5: 755-66.
13. Elzaouk L, Moelling K, Pavlovic J. Antitumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol. 2006; 15: 865-74.
14. Nakamizo A, Marini F, Amano T, et al Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005; 65: 3307-18.
15. Chen XC, Wang R, Zhao X, et al Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. Carcinogenesis. 2006; 27: 2434-41.
16. Studeny M, Marini FC, Champlin RE, et al Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002; 62: 3603-8.
17. Nakamura K, Ito Y, Kawano Y, et al Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004; 11: 1155-64.
18. Mohr A, Lyons M, Deedigan L, et al Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med. 2008; 12: 2628-43.
19. McMahon JM, Conroy S, Lyons M, et al Gene transfer into rat mesenchymal stem cells: a comparative study of viral and non-viral vectors. Stem Cells Dev. 2006; 15: 87-96.
20. Pfeifer A, Ikawa M, Dayn Y, et al Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci USA. 2002; 99: 2140-5.
21. Reiser J, Harmison G, Kluepfel-Stahl S, et al Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci USA. 1996; 93: 15266-71.
22. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol. 1998; 10: 573-80.
23. Maeshima Y, Sudhakar A, Lively JC, et al Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science. 2002; 295: 140-3.
24. 45-132-TNF. IUBMB Life. 2006; 58: 647-53.
25. Breyer A, Estharabadi N, Oki M, et al Multipotent adult progenitor cell isolation and culture procedures. Exp Hematol. 2006; 34: 1596-601.
26. Qian H, Yang H, Xu W, et al Bone marrow mesenchymal stem cells ameliorate rat acute renal failure by differentiation into renal tubular epithelial-like cells. Int J Mol Med. 2008; 22: 325-32.
27. Lois C, Hong EJ, Pease S, et al Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002; 295: 868-72.
28. Zhang XY, La Russa VF, Reiser J. Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins. J Virol. 2004; 78: 1219-29.
29. Qiao C, Xu W, Zhu W, et al Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int. 2008; 32: 8-15.
30. Zhang Z, Li M, Wang H, et al Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA. 2003; 100: 11636-41.
31. Ren C, Kumar S, Chanda D, et al Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells. 2008; 26: 2332-8.
32. +-derived and monocyte-derived dendritic cells. J Immunol. 2006; 177: 2080-7.
33. Stoff-Khalili MA, Rivera AA, Mathis JM, et al Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat. 2007; 105: 157-67.
34. Studeny M, Marini FC, Dembinski JL, et al Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004; 96: 1593-603.
35. Xin H, Kanehira M, Mizuguchi H, et al Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells. 2007; 25: 1618-26.
36. Kucerova L, Altanerova V, Matuskova M, et al Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007; 67: 6304-13.
37. Kanehira M, Xin H, Hoshino K, et al Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther. 2007; 14: 894-903.
38. Chen X, Lin X, Zhao J, et al A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther. 2008; 16: 749-56.
39. Tandle A, Hanna E, Lorang D, et al Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer. 2009; 115: 128-39.
40. Borsi L, Balza E, Carnemolla B, et al Selective targeted delivery of TNFalpha to tumor blood vessels. Blood. 2003; 102: 4384-92.
41. Mocellin S, Rossi CR, Pilati P, et al Tumor necrosis factor, cancer and anti-cancer therapy. Cytokine Growth Factor Rev. 2005; 16: 35-53.
42. Maeshima Y, Colorado PC, Torre A, et al Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem. 2000; 275: 21340-8.
43. Maeshima Y, Colorado PC, Kalluri R. Tw o RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem. 2000; 275: 23745-50.
44. Maeshima Y, Manfredi M, Reimer C, et al Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem. 2001; 276: 15240-8.